Cure8 news brief
The study suggests that elderly-onset IBD patients have similar mortality and many age-related complication rates compared with elderly people without IBD, but they have higher abdominal surgery risk and lower use of thiopurines and anti-TNF compared with younger-onset patients — which could influence treatment decisions and surgical planning.
Older adults with new IBD diagnoses, clinicians who manage geriatric IBD patients, surgeons, and researchers studying treatment patterns and outcomes in elderly-onset IBD.
The study used a national registry (epi-IIRN) and matched EO-IBD cases to non-IBD controls and to AO-IBD patients to estimate risks over time, accounting for death as a competing risk.
Reported key comparisons include mortality rates per 1,000 person-years, adjusted hazard ratios for medication exposure (thiopurines and anti-TNF), and surgery risks (abdominal and perianal) for Crohn’s disease and ulcerative colitis.
The main practical points the authors highlight are that EO-IBD did not increase overall mortality versus age-matched peers and that older-onset patients had lower use of immunomodulators and biologics but higher abdominal surgery risk than younger-onset patients.
How this may be used These results suggest clinicians may need to consider surgical risk and individualized treatment strategies in older-onset IBD, while balancing the lower observed exposure to immunosuppressive therapies in this group.
This is an observational nationwide registry study; associations do not prove causation. Medication exposure differences may reflect prescribing choices, comorbidities, or contraindications in older patients rather than efficacy. The report is from a national Israeli database (epi-IIRN) and appears to be peer-reviewed by the hosting site.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
Patients and clinicians often need real-world data on how methotrexate is actually used in IBD outside trials—this study shows it’s commonly paired with biologics, usually given subcutaneously, and has a median use of...
This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.
